Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CSL ( (AU:CSL) ) has issued an announcement.
CSL Limited announced a change in the director’s interest, specifically regarding Ms. Alison Watkins AM. The change involves the acquisition of 427 rights under the CSL Limited Non-Executive Director Rights Plan, with a consideration of $93,670.26. This move reflects the company’s ongoing commitment to aligning director interests with shareholder value, potentially impacting CSL’s governance and stakeholder confidence positively.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$282.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and manufacturing of innovative medicines and vaccines. The company is known for its work in the areas of immunology, hematology, and influenza vaccines, serving a global market with a strong emphasis on research and development.
Average Trading Volume: 990,597
Technical Sentiment Signal: Sell
Current Market Cap: A$104.2B
Find detailed analytics on CSL stock on TipRanks’ Stock Analysis page.